This Annals of Surgical Oncology Journal CME/MOC activity consists of a journal article, a self-assessment exam, and an evaluation.

• describe the role of neoadjuvant therapy in resectable pancreatic cancer
• identify the complexity of diagnostic quality assurance to ensure a homogenous population in studying resectable pancreas cancer outcomes
• assess the importance of an R0 resection, its definition and its role as the optimal outcome measures for the benefit of neoadjuvant therapy
• describe the potential benefits of a neoadjuvant approach in resectable pancreas cancer

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Society of Surgical Oncology designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The SSO has approved this activity for up to 1 self­-assessment credit which meets the requirement of the self­-assessment component, Part II of the American Board of Surgery (ABS) Maintenance of Certification (MOC) Program.

This online activity consists of an article, a self-assessment exam, and an evaluation. To receive AMA PRA Category 1 Credit™ and self-assessment credit, participants must watch the webinar, successfully complete the self-assessment exam, and achieve a minimum score of 75% on the exam. The self-assessment exam includes 4 multiple choice questions. Learners will be asked to read each question, select an answer, and review the section of the webinar where the answer is found. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a post-activity evaluation. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.

The estimated time to complete this entire activity is 1 hour.

Release Date

June 23, 2020

Expiration Date    

June 23, 2021

In accordance with the ACCME’s Accreditation Criteria, the Society of Surgical Oncology must ensure that anyone in position to control the content of this educational activity has disclosed all financial relationships with a commercial interest. All educational planners, authors, reviewers, and other individuals in a position to control or influence the content of this activity were required to disclose all financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The ACCME also requires that the Society of Surgical Oncology resolve any reported conflict of interest and ensure the educational content of this activity is vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.

All identified conflicts of interests have been resolved.

Authors

Andrew Barbour, Jaswinder S. Samra, Koroush Haghighi, Mark Donoghoe, Matthew Burge, Marion Harris, Yu Jo Chua, Jenna Mitchell, Nick O'Rourke, Howard Chan, Val Gebski, Sivakumar Gananadha, Daniel Croagh, and James Kench have disclosed no conflicts of interest.

David Goldstein: Celgene - Research Grant to Institution; Zucero - Research Grant to Institution 

Peer Reviewers

Reviewers A and B have disclosed no conflicts of interest.

Reviewer names have been withheld for reasons of confidentiality, in keeping with the Annals of Surgical Oncology blind review policy and process for manuscript submission and acceptance.

Planners, Reviewers, and Staff

David Kooby, MD, Section Editor, Annals of Surgical Oncology, has disclosed no conflicts of interest.

Kyo Chu, MD, Disease Site Work Group Planner: Castle Biosciences - Consultant - Advisory Board

Marissa Howard-McNatt, MD, Chair at the time of review, CME/CPD Committee, has disclosed no conflicts of interest.

Vikas Dudeja, MD, CME/CPD Committee Reviewer, has disclosed no conflicts of interest.

Deborah A. Whippen, Managing Editor, Annals of Surgical Oncology, has disclosed no financial relationships. (Planner/Staff)

Julie Smith, Editorial Manager, Annals of Surgical Oncology, has disclosed no financial relationships. (Planner/Staff)

Kelley Gazer, SSO Staff, Annals of Surgical Oncology, has disclosed no financial relationships. (Planner/Staff)

The primary purpose of the Society of Surgical Oncology's journal-CME is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.

For information about the Society of Surgical Oncology’s privacy policy and associated disclaimer, please visit this site: http://www.surgonc.org/disclaimer.